Cytek Biosciences (STU:8EQ) Other Current Receivables: €1.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8EQ Cytek Biosciences Inc STU:8EQ
70 GF Score
Price €3.96
GF Value €4.74
! 6 Warning Signs
View Full Analysis

What is Cytek Biosciences Other Current Receivables?

Cytek Biosciences STU:8EQ +10.00% 70 Other Current Receivables is €1.4 Mil as of Jun. 2026. GuruFocus rates STU:8EQ with a GF Score™ of 70/100 and a GF Value™ of €4.74. The stock has 6 warning signs investors should review.

Cytek Biosciences's Other Current Receivables for the quarter that ended in Jun. 2026 was €1.4 Mil.

Cytek Biosciences's quarterly Other Current Receivables declined from Dec. 2025 (€8.21 Mil) to Mar. 2026 (€3.96 Mil) but then stayed the same from Mar. 2026 (€3.96 Mil) to Jun. 2026 (€1.39 Mil).

Cytek Biosciences's annual Other Current Receivables declined from Dec. 2023 (€0.18 Mil) to Dec. 2024 (€0.00 Mil) but then increased from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€8.21 Mil).

Cytek Biosciences Other Current Receivables Related Terms

Cytek Biosciences Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Cytek Biosciences's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytek Biosciences Other Current Receivables Chart

Cytek Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial -0.11 1.90 0.18 0.00 8.21

Cytek Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 4.30 8.21 3.96 1.39
STU:8EQ
70GF Score
Cytek Biosciences Inc STU:8EQ
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytek Biosciences Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €1.4 Mil mean?
Cytek Biosciences (STU:8EQ) has a Other Current Receivables of €1.4 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cytek Biosciences and its competitors.
Is Cytek Biosciences' Other Current Receivables too high?
Cytek Biosciences' current Other Current Receivables is €1.4 Mil. Overall, Cytek Biosciences has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Other Current Receivables compare to CERS and TCMD?
Cytek Biosciences' Other Current Receivables of €1.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cytek Biosciences and its competitors. Cytek Biosciences's current Other Current Receivables is €1.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Cytek Biosciences (STU:8EQ) has a current Other Current Receivables of €1.4 Mil. The stock's GF Value™ is €4.74, compared to a current price of €3.96 — trading 16.5% below its estimated fair value. The current Other Current Receivables is €1.4 Mil. Cytek Biosciences' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Cytek Biosciences (STU:8EQ), the current Other Current Receivables is €1.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytek Biosciences (STU:8EQ) Overvalued in 2026?

Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued. The current stock price of €3.96 is trading 16.5% below its estimated GF Value™ of €4.74.

Key valuation signals for STU:8EQ:

  • Other Current Receivables: €1.4 Mil
  • GF Value™: €4.74 vs. price of €3.96 (16.5% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the STU:8EQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytek Biosciences Business Description

Other Exchanges CTKB:USA8EQ:Germany
Address 47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
70GF Score

Get the complete analysis for STU:8EQ

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.96
Price
€4.74
GF Value